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Abstract: Viruses employ an array of elaborate strategies to overcome plant defense
mechanisms and must adapt to the requirements of the host translational systems. Pokeweed
antiviral protein (PAP) from Phytolacca americana is a ribosome inactivating protein (RIP)
and is an RNA N-glycosidase that removes specific purine residues from the sarcin/ricin
(S/R) loop of large rRNA, arresting protein synthesis at the translocation step. PAP is thought
to play an important role in the plant’s defense mechanism against foreign pathogens.
This review focuses on the structure, function, and the relationship of PAP to other RIPs,
discusses molecular aspects of PAP antiviral activity, the novel inhibition of this plant toxin
by a virus counteraction—a peptide linked to the viral genome (VPg), and possible
applications of RIP-conjugated immunotoxins in cancer therapeutics.
Keywords: pokeweed antiviral protein; ribosome inactivating protein; virus genome-linked
protein; sarcin/ricin loop; immunotoxin
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1. Introduction
An evolutionary arms race between plants and their pathogens has shaped each other’s elaborate
strategies for survival. Many plants produce toxic proteins that are thought to play a key role in their
defense mechanisms against foreign pathogenic invaders. These anti-pathogenic protein toxins are
known as ribosome inactivating proteins (RIPs). RIPs are broadly distributed throughout the kingdom
of plants, fungi, and have been identified in several species of bacteria. High toxicity of the castor
(Ricinus communis) and jequirity (Abrus precatorius) bean plants owe their detrimental physiological
effects toward eukaryotic cells to these poisons and have been known since antiquity [1]. The deadliness
of many RIPs has been explored by political and military organizations to design biological
weaponry [2–4], many scientists to generate transgenic species of plants resistant to viral and fungal
infections [5,6], numerous cancer researchers in production of immuno-conjugate therapeutics [7–9],
as well as mystery writers to engage the readers [10]. RIPs are RNA N-glycosidases that inhibit advanced
stages of protein synthesis by selectively modifying large rRNA molecules and deactivating ribosomes [11].
Other plants (e.g., common pokeweed—Phytolacca americana and common soapwart—Saponaria
officinalis) produce pokeweed antiviral protein (PAP) [12] and saporin [13], respectively, with increased
antiviral and antifungal activities. Presently, evidence for the lack of RIPs has been obtained solely for
Arabidopsis thaliana, as this plant does not express detectible amounts of RIPs nor contains a sequence
that encodes for any putative RIP in its genome [14]. Generally, RIPs being potent cellular toxins are
exported out of the cell once they are synthesized, and localized within the cell wall matrix [15]. It is
hypothesized that they gain access into the cytoplasm as the pathogen enters the cell, thus promoting
their activity by impairing host ribosomes [16].
2. Pokeweed Antiviral Protein: One of a Number of Ribosome Inactivating Proteins
2.1. Introduction to the Ribosome Inactivating Proteins
The term “ribosome inactivating protein” came about before the structure and enzymatic activities of
RIPs were realized. After the mechanism of action of RIPs on ribosomes became clear, the name is used
for these N-glycosidases [EC 3.2.2.22]. Enzymes known as proteases and RNases inactivate or damage
ribosomes by different mechanisms, and may not be classified as RIPs [17].
2.1.1. Classification of Pokeweed Antiviral Protein among Other Ribosome Inactivating Proteins
The first acknowledged RIPs were ricin and abrin [18,19]. However, only in 1971 ricin was
recognized as an inhibitor of eukaryotic protein synthesis [20]. It was not established until several years
later that the inhibition of protein synthesis was due to the impairment of host ribosomes [21]. PAP was
also reported to impair protein synthesis through a related mechanism [22].
Classification of RIPs into holo- and chimero-subgroups was founded on their physical properties,
the number of polypeptide chains, and posttranslational modifications (Figure 1) [23,24]. Holo-RIPs,
having a single RNA N-glycosidase domain, are frequently referred to as type 1 RIPs. These consist of
a single intact polypeptide of ~30 kDa [12,25]. Type 1 RIPs are strongly basic proteins that are clearly
distinct in their global sequence homology and posttranslational alterations, yet share several active site
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residues and secondary structure elements [26–28]. Examples of type 1 RIPs include PAP, saporin, and
barley (Hordeum vulgare) translational inhibitor. Type 1 RIPs inhibit cell-free protein synthesis and are
only mildly toxic to cells and animals. The majority of characterized RIPs fall into this category [25].
Among type 1 RIPs, the 3D structures of saporin, momordin (MOM), PAP, trichosanthin and gelonin
have been determined and their properties characterized [26,29–32]. Fifteen isoforms of saporin from
S. officinalis have been characterized, differing in ribosome translation inhibition activities and cellular
toxicity [33]. Crystal structure at 2.0 Å resolution of isoform 6 of saporin (SO6) has been reported with
a structural motif that includes three lysyl residues in its C-terminal region—a highly conserved motif
in all RIPs [29]. X-ray crystal structure of PAP has been determined [34] with various active site
inhibitors and rRNA substrate analogues. Graphical Abstract presents a low temperature structure of
PAP (PDB ID 1QCI).

Figure 1. Schematic depiction of the structure of ribosome inactivating proteins (RIPs).
Chimero-RIPs contain two structurally and functionally distinct domains: the catalytic RNA
N-glycosidase domain and the carbohydrate (lectin properties) binding domain, and are better known as
type 2 RIPs. Examples of these acutely toxic heterodimeric proteins include ricin, abrin and modeccin.
Their amino-terminal domain is equivalent to the catalytic domain of type 1 RIPs—the RIP activity
domain, often referred to as the A-chain (e.g., RTA—ricin A-chain). The catalytic domain is disulfide
bridge-linked to an evolutionary divergent carboxyl-terminal B-chain, possessing sugar-binding
properties of ~30 kDa [35–37]. Galactosyl moieties of glycoproteins and/or glycolipids, localized on the
exterior of eukaryotic cells [38–40], are bound by the lectin chains of type 2 RIPs. This binding promotes
the reverse transport of the A-chain to the cytosol [41–43]. Once inside the cell, the RIP accesses
translational machinery and depurinates ribosomes. Extracellular location of RIPs prevents contact
between these poisons and the ribosomes of healthy cells, yet provides an immediate source of the toxin
when a pathogen infects the cell. The type 2 RIPs have proven to be invaluable for studies of endocytosis
and intracellular transport into mammalian cells [44–46]. It is not clear how type 1 RIPs are distributed
within the extra-cellular spaces of the host cells, although primary structure analysis points to fatty acid
binding sequences within their sequences [15,47]. Clear evidence however, has been presented for PAP
retro-translocation from the endoplasmic reticulum into the cytosol [48].
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Type 3 RIPs are synthesized as inert precursors (pro-RIPs), and undergo proteolytic modifications to
acquire their enzymatically activity [23]. These RIPs are much less common than either type 1 or
type 2 RIPs. Type 3 RIPs have been identified from maize (Zea mays) and barley (from H. vulgare) [49–52].
2.1.2. Distribution of Ribosome Inactivating Proteins
RIPs are broadly dispersed among plants, fungi, alga, and several species of bacteria [25,53,54].
Additionally, RIP-type activity has been reported in animal tissues as well [55]. A large number of RIPs
has been identified in a small group of families, namely Carylphyllaceae, Cucurbitaceae, Euphorbiaceae,
Sambucaceae, Phytolaccaceae and Poaceae [24]. Synthesis of some RIPs could be induced by factors,
such as senescence [56], viral infection [57], development [51] and stress [58].
The molecular weight of type 1 RIPs ranges within 21–38 kDa. As for type 2 RIPs, the molecular
weights of the two-chain peptide range from 56 to 69 kDa [24]. Bacterial RIPs Stx1 and Stx2 from
Escherichia coli (E. coli) promote their enzymatic activity similar to their plant analogues [59–63].
Research reveals that RIPs are found in several fungi species [64–67]. At least one RIP has been isolated
from alga, Laminaria japonica A. [68]. All of the above findings favor the generally accepted hypothesis
that RIPs are enzymes widely distributed in nature, and therefore play pivotal undefined biological roles.
Pokeweed Antiviral Protein and Its Isoforms
Most type 1 RIPs are encoded by intron-less genes that define pro-RIPs with N- and C-terminal
extensions with respect to the mature forms, e.g., several isoforms of pokeweed antiviral protein from
P. americana have been described (Table 1) [12,24,69–71]. All of them possess pronounced antiviral
properties and high enzymatic activity on ribosomes from diverse phyla. These isoforms are encoded by
a gene family composed of approximately nine members [69]. PAPI (or simply PAP), PAP-II and
PAP-III are the leaf isoforms that appear in spring, early and late summer, respectively [12,69–73],
whereas PAP-S1 and PAP-S2 are the isoforms isolated from seeds and have been shown to exhibit the
highest activity in vitro of all the isoforms [74–76]. PAP and PAP-S1 share 76% sequence identity,
PAP-S1 and PAP-S2 have 83%, whereas PAP and PAP-II are only 33% identical [76,77]. A further
isoform, α-PAP, is similar in sequence to PAP-S1, and essentially expressed in all organs [76,77];
it shares 74% identity with PAP. PAP-R has been isolated from roots of the pokeweed plant [24,78] and
PAP-H is from hairy roots [24,79]. Moreover, RIP-free callus and suspension cultures of P. americana
have been attained [24,80]. Perhaps, a gene-silencing event occurred during the establishment of the
cultures because RIP-isoforms are ubiquitously expressed in all organs of the plant [77].
The genes of PAP [69], PAP-II [72] and PAP-S [81] have been isolated from tissue specific cDNA
libraries and sequenced. The PAP gene carries an open reading frame of 939 nt coding for the mature
PAP protein (262 amino acids) plus an N-terminal signal peptide of 22 amino acids [69] and a C-terminal
extra peptide of 29 amino acids [30]. This gene has been expressed in E. coli cells under an inducible
(lac) promoter with an extremely low yield (0.13%–0.16% of the total bacterial protein) [82]. It was
found that even the low level of gene expression slowed down bacterial growth significantly.
Chen et al., also found that elimination of N-terminal signal peptide codons (22 amino acids) from the
PAP gene led to an immediate cell death [82]. The authors have concluded that PAP is highly toxic (in vivo)
for prokaryotic cells [83]. Crystal structure of PAP-I, α-PAP, and PAP-II have been determined at
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different resolutions [30,34,84]. PAP-S differs from other PAP isoforms; it is associated with three
N-acetylglucosamine residues covalently attached to the protein’s asparagine residues [85]. Based on
the X-ray and molecular modeling studies, PAP-III is predicted to have a greater anti-HIV activity due
to its topology and charge distribution [86]. Moreover, modeling studies have indicated that PAP is able
to accommodate a guanine base in its active pocket without large conformational changes, and this
prediction was experimentally confirmed [87].
Table 1. Isoforms of Pokeweed Antiviral Protein [24]. ND: Not Determined.
Isoform

Source

Number of
Aminoacyl
Residues

PAP-I

Spring Leaves

262

29

PAP-II
PAP-III

Early Summer Leaves
Late Summer Leaves

285
285

30
30

PAP-S1

Seeds

262

29

PAP-S2

Seeds

262

29

α-PAP

Expressed in
All Organs
Roots
Hairy Roots
Tissue Culture

261

28.9

271
268
262

29.8
29.5
29

PAP-R
PAP-H
PAP-Culture

MW (kDa),
Mature
Protein

Activity (RC50)
1.5 nM Rat Liver Ribosomes;
4.7 nM E. coli Ribosomes
ND
ND
3.2 nM Rat Liver Ribosomes;
280 nM E. coli Ribosomes
3.6 nM Rat Liver Ribosomes;
1000 nM E. coli Ribosomes
1.3 nM Rat Liver Ribosomes;
25 nM E. coli Ribosomes
ND
ND
ND

References

[70]
[70]
[86,88]
[75,76]
[75,76]
[76]
[89]
[90]
[91]

2.2. Biological and Enzymatic Activities of Ribosome Inactivating Proteins
Distinct biological activity of both type 1 and type 2 RIPs has served as the basis for their identification.
Type 2 RIPs owe their toxicity and cytotoxicity to the deviations in the lectin activity and specificity of
the B-chain, and present with significant differences in their cytotoxicity. Ricin, for instance, is known
to induce 50% apoptosis in cells at concentrations below 1 ng/mL, while some elderberry type 2 RIPs
display no significant effects at 1 mg/mL [78].
The inhibitory effect of PAP on tobacco mosaic virus (TMV) transmission was reported in 1925 by
Duggar and Armstrong [79], yet PAP was not acknowledged as a protein synthesis inhibitor until 1978 [80].
Myriad type 1 RIPs are antiviral proteins. Type 1 RIPs are not as cytotoxic as type 2 RIPs, since they
are not able to cross the cell membrane on their own. Nevertheless, a number of specialized animal cells
are able to import type 1 RIPs by endocytosis, and consequently are susceptible to the RIP activity.
Monomeric protein synthesis inhibitors share a significant sequence identity with ricin’s A-chain (RTA).
Further, ricin, abrin, and PAP inhibit cell-free protein synthesis by permanent inactivation of the
ribosomes by means of arresting the function of elongation factors EF-1 and EF-2 [25,92].
It is well known that some RIPs possess multiple enzymatic activities. Some RIPs act on rRNA at
specific single sites [93]; yet others were shown to depurinate multiple adenines from various nucleic
acid substrates, such as herring sperm DNA, poly(A), tRNA, and even TMV RNA [94]. Site-specific
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RNA N-glycosidase activity (Figure 2) toward ribosomes, rRNA, and depurination of mRNA and viral
RNA are briefly discussed below.

Figure 2. Schematic representation of the action sites for RNA N-glycosidase activity,
polynucleotide:adenosine glycosidase (PAG) activity, and presumed DNase-like and
phosphatase activity of RIPs.
2.2.1. Site-Specific RNA N-Glycosidase Activity towards Ribosomes and Naked rRNA
Ricin and other RIPs recognize a specific and universally conserved region within the large 28S rRNA,
and cleave a glycosidic bond between an adenine and the nucleotide on the RNA [95]. For rat liver
ribosome, this distinct site is A4324, and it is positioned within a single-stranded loop referred to as the
sarcin/ricin (S/R) loop. The S/R loop is located within the domain VII of the 28S rRNA (Figure 3) [25,96].
After the adenine is removed, the depurinated site becomes subject to a β-elimination hydrolysis when
treated with acidic aniline. This promotes cleavage of the 3'-end of the rRNA, and the depurination
product can be detected by electrophoresis. This site-specific RNA N-glycosidase activity is a common
characteristic attributed to all RIPs. Schramm et al., showed that the transition state of the ricin reaction
develops an oxocarbenium character on the ribose [97]. Furthermore, it was established that RTA
operates via a DN*AN mechanism [98]. This was further confirmed by the synthesis of novel compounds
that incorporated the cationic character, such as amines, into a ribose analogue. As expected for true
transition state analogues, these were potent, tightly binding, ricin inhibitors [98]. Tanaka et al., have
used the RTA transition state knowledge to design and synthesize a high affinity inhibitor of the RTA
catalytic site [98]. PAP and other RIPs inhibit the translocation step of elongation [99]. Specifically,
PAP inhibits Ty1-directed +1 ribosomal frameshifting and retrotransposition [100,101].
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Figure 3. Structure of rRNA substrates for N-glycosidase activity of RIPs: (e) E. coli;
(h) Homo sapiens; (m) Mus musculus; (o) Oryza sativa; (r) Rattus rattus;
(s) Saccharomyces cerevisiae; (x) Xenopus laevis.
The S/R loop within the rRNA of different ribosomes is universally conserved across all species
(Figure 3) [24]. Consequently, the specificity of different RIPs for their substrates, and the sensitivity
between ribosomes among species are likely to come from deviations within RIPs themselves and the
ribosomal proteins. Ricin presents highest activity toward yeast and mammalian ribosomes, but exhibits
low activity on plant and E. coli ribosomes [25], whereas PAP depurinates ribosomes from plants,
bacteria, yeasts, and lower and higher animals [25]. RIP substrate accessibility may be influenced by the
deviations in ribosomal proteins that would dictate RIP activity and sensitivity towards different
ribosomes. The L9 and L10e rat liver ribosomal proteins are targeted by the ricin A chain (RTA) [102],
however PAP has been shown to bind to the L3 yeast ribosomal protein [103,104]. Transgenic plants,
expressing truncated L3 ribosomal protein, confer resistance to PAP [104]. Furthermore, broad-spectrum
activity of PAP towards different ribosomes may be explained by the fact that the L3 ribosomal protein
is highly conserved. Pokeweed ribosomes were shown to be as sensitive to PAP treatment as wheat
ribosomes [16]. The rRNA in native ribosomes is the ideal substrate for RIPs, nonetheless, protein-free
rRNA [105] and synthetic oligoribonucleotides that mimic the S/R domain [106,107], serve as substrates
for RIP activity as well. All RIP depurinate the equivalent adenine residue from naked rRNA as from
native ribosomes, but many of them depurinate naked rRNA at multiple sites. In addition, several RIPs
are able to depurinate naked rRNA from non-substrate ribosomes. For instance, ricin is able to act on
naked E. coli 23S rRNA, however possesses no activity against the intact E. coli ribosomes. Moreover,
several RIPs are able of depurinating guanine residues within their substrates [34,108].
2.2.2. Depurination of Capped and Uncapped mRNA; Antiviral Action of PAP
Advances in high-performance liquid chromatography (HPLC) coupled to fluorescent methods of
detection, allowed researchers to detect, identify, and quantify possible reaction products of RIPs and
the amount of free adenine released from different substrates by RIPs [107,109]. These techniques allow
for direct measurement of ribosomal depurination, quantification of released purines, and also aided in
identification of some uncommon activities of RIPs. For instance, various RIPs serve as effective
inhibitors of animal and/or plant viruses. Depurination of viral RNA by RIPs is a novel activity, and any
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insights into the mechanism of substrate selectivity and specificity may be of paramount importance in
the search for the potent antiviral agents. The mode of action for the antiviral activity of RIPs is poorly
understood, however this activity does not depend solely on the ribosomal inactivation. An alternative
mechanism may involve a direct interaction of RIP with viral RNA or DNA, with additional effects
brought about by the eukaryotic translation initiation factors (eIFs). Pokeweed antiviral proteins PAP-I,
PAP-II, and PAP-III cause a concentration-dependent depurination of genomic HIV-1 RNA [88,110,111],
TMV RNA [112], poliovirus [113], herpes simplex virus [114], influenza virus [115], brome mosaic virus
(BMV) [116], lymphocytic choriomeningitis virus (LCMV) [117], tobacco etch virus (TEV) RNA [107],
and inhibits Japanese encephalitis virus infection, both in vitro and in vivo [118]. In contrast, the RTA
does not depurinate same viral RNAs to produce detectable quantities of purines.
A novel mechanism for the inhibition of translation by PAP has been put forward [119]. This
inhibition of translation is based on a specific depurination of capped mRNA. Hudak et al., used wild
type (WT) PAP and three different PAP mutants (PAPx, an active site mutant (E176V); PAPn, a mutant
with a substitution (G75D) in the amino-terminal sequence; PAPc, a mutant lacking the carboxyl-terminal
25 amino acid residues) that do not depurinate tobacco or rabbit ribosomes, and have shown that PAP
inhibits the in vitro translation of BMV and potato virus X RNAs without ribosomal depurination [119].
This shows that PAP is able to differentiate between capped and uncapped mRNAs, since PAP, and
some of its mutants, inhibited the translation of capped (but not uncapped) luciferase transcripts.
Presence of m7GTP analogue lowers translational inactivation activity of PAP and PAP mutants,
implying that these RIPs are able to recognize the cap structure on the mRNAs [120]. PAP-treated
luciferase transcripts revealed that the capped, but not the uncapped RNAs were subject to degradation
by acidic aniline, and therefore were depurinated in vitro. It was concluded that PAP may inhibit
translation by binding to the cap structure and depurinating the RNA, and that depurination of capped
viral RNA may be the principal mechanism for the antiviral activity of PAP [120]. Baldwin et al. [121]
have characterized the interactions of PAP with m7GTP cap analogue using fluorescence spectroscopy,
and these interactions were previously identified as competitive [107]. Zoubenko et al., have presented
evidence that PAP depurinates tobacco ribosomes in vivo by removing more than one adenine and a
guanine [122]. Moreover, PAPn mutant did not bind ribosomes efficiently pointing to the importance of
Gly-75 for PAP to bind ribosomes. Unlike wild type PAP (or the C-terminal PAPC mutant), PAPn did
not trigger production of salicylic acid in transgenic plants [122].
These results depict a promising mechanism to explain the antiviral activity of PAP, however, some
queries remain. For instance, the above-proposed mechanism does not clarify the inhibitory effect of PAP
on the replication of uncapped viruses such as influenza [115] and poliovirus [113]. Vivanco et al., [123]
have examined the activity of PAP against a variety of capped and uncapped viral RNAs, and
demonstrated that PAP does not depurinate every capped RNA, and that it can inhibit translation of
uncapped viral RNAs in vitro without causing detectable depurination. PAP depurinated the capped
TMV and BMV RNAs, but did not depurinate the uncapped luciferase RNA, indicating that PAP can
distinguish between capped and uncapped RNAs, but no detectable depurination of capped alfalfa
mosaic virus (AMV) RNA was recorded. This implies that recognition of the cap structure alone is not
sufficient for depurination of RNAs [123]. Moreover, PAP did not cause detectable depurination of
uncapped RNAs from tomato bushy stunt virus (TBSV), satellite panicum mosaic virus (SPMV), and
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uncapped RNA containing poliovirus IRES (internal ribosome entry site); however, in vitro translation
experiments showed that PAP inhibited translation of the above viral RNAs [123].
2.2.3. Effects of eIFs and RNA Secondary Structure—Missing Links in PAP-Substrate Selectivity
Wang et al. [124] presented evidence that PAP binds to eIF4G and its isoform eIFiso4G. In wheat
(Triticum aestivum), two forms of eIF4G exist, which differ in size, 180 (eIF4G) and 86 kDa (eIFiso4G),
and they bear only 30% amino acid identity [125,126]. PAP binds to m7GTP-Sepharose and this
interaction does not diminish the binding of PAP to purified eIFiso4G, indicating that a complex can
form between the cap structure, PAP and eIFiso4G. In the presence of wheat germ lysate, PAP
depurinated uncapped transcripts having a functional WT 3'translational enhancer sequence (3'TE), but
did not depurinate messages containing a non-functional mutant 3'TE [124]. This result supports earlier
hypothesis that binding of PAP to eIF4G and eIFiso4G could provide a mechanism for PAP to access both
uncapped and capped viral RNAs for depurination. In support to the above findings, Baldwin et al. [121]
have shown that PAP not only binds to the initiation factor scaffolding protein eIFiso4G, but that binding
of cap analogue to PAP is increased by these protein-protein interactions, suggesting a model where
PAP interacts with eIFiso4G/eIF4G (as part of the eIFiso4F/eIF4F complex) and binds to the cap region
of mRNA. Furthermore, addition of eIFiso4E/eIF4E (as part of the eIFiso4F/eIF4F complex) lowers the
binding affinity of PAP for the cap competitively because both are specific cap-binding proteins.
The ability of PAP to lower infectivity of both capped and uncapped RNA viruses suggests the presence
of a different, other than m7G cap, requirement that may influence PAP substrate recognition, binding,
and its antiviral activity. This was further supported by the pull-down assay and the Fluorescence
Resonance Energy Transfer (FRET) experiments, where Cheng et al. showed that the formation of a
triplex complex between PAP, eIFiso4E and eIFiso4G dramatically increase FRET energy transfer upon
binding of the eIFiso4G to the binary PAP-eIFiso4E complex [127]. This triplex protein interaction
demonstrates that eIFiso4G plays a key role in the regulation of PAP binding.
Elements within RNA secondary structures have been identified to play differentiated roles in PAP
binding to various structured RNAs. The 3'-UTRs of the non-polyadenylated plant viral mRNAs of TMV
and BMV are known to increase both the stability and the translational efficiency of a message [128,129]
in carrot protoplasts, whereas those of turnip mosaic (TYMV) and AMV viruses show no (or lowered)
effect on gene expression [129]. PAP depurinating activity on these structural viral RNAs correlates to
the 3'-UTRs translational effect [130]. Moreover, the presence of the eIFs reveal drastic differences in
the activity of PAP for its viral substrates, in a way that eIFiso4F (complex of eIFiso4E and eIFiso4G)
promotes increased affinity (and activity) of PAP for the TMV and BMV RNAs, whereas there is a
negligible effect of eIFiso4F on the binding to the TYMV and AMV, and no profound effect on the
depurination of the these RNAs [131]. These PAP-eIF-RNA interactions possibly promote PAP active
site structural changes, allowing PAP to recognize purine residues for depurination.
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2.3. Physiological Role, Toxicity of RIPs and Immunotoxins
2.3.1. Physiological Role of RIPs
Presently, there is no unequivocal and agreeable answer to why plants produce and accumulate RIPs,
despite the comprehensive knowledge of their structure, activity, and action mechanism. RIPs are
synthesized in many, but not all, plant species. Sequencing of the genome of A. thaliana provided no
evidence of RIP encoding genes [14]. This suggests that RIPs are not ubiquitous among plant species,
and do not play a universal role in their growth, development, or defense. Some facts support the notion
that RIPs play a defense function in plants. Only type 2 RIPs are able to gain entree to the cytoplasm of
intact cells via a receptor-lectin-mediated uptake process [25,132]. Toxicity of type 2 RIPs is restricted
to animal cells because bacteria and fungi are protected by a cell wall; type 2 RIPs they must bind glycan
receptors on the cell surface to ensure their entry. Ricin and abrin are thought to protect the seeds of
these plants against plant-eating animals [133]. Type 1 RIPs have direct effect on yeast and plant
pathogenic fungi [134]. Recent studies show that transgenic tobacco plant lines (Nicotiana tabacum),
expressing an activated form of maize (Z. mays), a type 3 RIP, appear more resistant to larvae of the
cigarette beetle (Lasioderma Serricorne) and the tobacco hornworm (Manduca Sexta) than the wild type
plants [135], providing a resistance to these maize-eating insects. Presently though, there is no
documented oral toxicity of type 1 and 3 RIPs on higher animals. RIPs possess a set of unique biological
activities toward human and animal cells that could be exploited in antiviral drug therapeutics.
The antiviral activity of type 1 RIPs is well documented [136], although the underlying mechanism has
not been elucidated.
2.3.2. Toxicity of Ribosome Inactivating Proteins
Reports about the use of ricin and abrin for homicidal purposes go back to ancient times. Nonetheless,
usage of these toxins as regular weapons is a quite modern idea. The ease to acquire large amount of
ricin, for example, made this toxin a good candidate for bioterrorism.
In 1952 the US Army filed a patent on how to prepare ricin for weapon purposes [137]. Certainly the
extent to which ricin was collected for military purposes is not known. It was, however, intended to be
employed in assassination of Georgi Markov and Vladimir Kostov, exiled journalists who published
incriminate information about the corrupt life of the Bulgarian communist leadership [1,3]. Five more
instances were identified where this assassination technique was used. In the past decade ricin has been
associated with terrorist organizations in several countries. The availability of improved anti-ricin
vaccine [138] and better ability to trace and identify toxin in the body should make the toxin a less
tempting compound for use in bioterrorism [1,139].
In 2013, CNN Justice [140] has reported that the Texas actress, Shannon G. Richardson, was
sentenced to 18 years in prison after admitting last year that she sent ricin-tainted letters to the US
President Barack Obama and then New York City Mayor Michael Bloomberg.
Type 1 RIPs are certainly not as cytotoxic to higher animals, since they cannot cross the cell
membrane on their own [16]. Pokeweed plant synthesizes its toxin as a precursor and compartmentalizes
it within cell wall matrix [15]. This ensures that the pokeweed’s ribosomes never encounter its own
toxin, leaving overall protein synthesis unaffected. In contrast to the healthy appearance of pokeweed,
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the expression of PAP in transgenic N. tabacum plants leads to various physiological changes [5].
Transgenic tobacco plants producing high levels (more than 10 ng/mg protein) of PAP were sterile,
having a stunted, molted phenotype. This correlated with the level of PAP expressed. Plants producing
less than 1–5 ng PAP/mg protein were fertile and normal in appearance [5,134]. In recent studies,
Hudak et al., have shown PAP undergoing homodimerization as a mechanism to limit depurination of
pokeweed ribosomes [141].
2.3.3. Immunotoxins and Other Conjugates of RIPs
The first carrier-toxin hetero-conjugates of RIPs were prepared using polyclonal and later monoclonal
antibodies with toxins that were able to block protein synthesis at the ribosome level. Bio-specific agents
other than monoclonal antibodies (hormones, growth factors, antigens, cytokines, etc.) have also been
employed in developing cell-targeting conjugates [142]. Toxins of different types can be used to
construct effective immunotoxin (IT) conjugates, including plant, bacterial and fungal toxins. RIPs [54]
have been extensively used in preparation of such ITs. These chimeric ITs can be made with either
type 1 or type 2 RIPs [143]. The linkage of the carrier molecule to the toxin can be attained by chemical
cross-linking, indirect linking, or gene fusion [144].
Several lines of research have efficiently used PAP as a component of ITs, conjugated to a variety of
monoclonal antibodies. Jansen et al. [145] have used B43-PAP immunotoxin plus cyclophosphamide to
successfully treat human leukemia in mice with severe combined immunodeficiency (SCID).
Uckun et al., have used B43 (anti-CD19)-PAP IT in treatment of human pre-B acute lymphoblastic and
other types of leukemia in mice [146–149]. Erice et al. [150] have found that PAP conjugated to
monoclonal antibodies recognizing CD4, CD5, or CD7 antigens effectively inhibited HIV-1 replication
in normal CD4+ T cells infected with HIV-1 strain LAVBRU, as well as in activated T cells from two
asymptomatic HIV-1-seropositive individuals [151]. All of the above and many other lines of evidence
point toward potential therapeutic PAP-immunoconjugate applications of this protein against a variety
of cancer lines as well as HIV-1.
Liposomal delivery of RIPs may provide both hydrophilic, hydrophobic environments, enhancing
RIP solubility. It uses regulated drug release, and thus reduces or eliminates tissue damage on accidental
extravasation, and protects RIP from premature degradation, functions as a sustained release system, and
can substantially alter the pharmacokinetics of the RIP and reduce clearance [152]. As all of the above
properties of targeted liposomal employment of RIPs become surmounted, RIP-conjugated
immunotoxins may become an important new modality for cancer therapy. The major dose-limiting
toxicity of RIP-conjugated immunotoxin therapies is vascular leak syndrome (VLS) [153]. VLS is
characterized by an increase in vascular permeability accompanied by extravasation of fluids and
proteins resulting in interstitial edema and organ failure.
2.3.4. Interactions of PAP with VPg and the Inhibition of PAP Antiviral Activity
Researchers have undertaken extensive efforts in exploration of RIP properties and studies of their
toxicities in order to develop antidotes against their activity. Biochemical and structural characterization
of the catalytic domains of many RIPs, including RTA, served as an attractive target for structure-based
drug design. Our comprehension of the RIP action mechanism predominantly comes from the structural
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and mutagenesis work [154,155]. Advances in the X-ray crystallography allowed for the determination
of the high-resolution structures of RIP catalytic domains, and thus development of substrate analogues
that possess high affinity for the RIP active sites. Several categories of RIP inhibitors have been
developed. Thus far, effective small molecule RTA inhibitors are generally based on pterins, guanines,
pyrimidines, and stem-loop oligonucleotides. Schramm and his colleagues have developed transition
state analogues that have high affinities for the RTA active site; these however, only bind at acidic pH,
around 4 [97,98]. In recent years, RIP activity of PAP was shown to be inhibited by a viral
peptide—genome-linked protein, VPg isolated from the turnip mosaic potyvirus (TuMV) [107]. High
affinity of the viral peptide for PAP (Kd = 29 nM), and its ability to inhibit PAP enzymatic activity,
provides a new direction in search for a novel generation of RIP inhibitors.
The genus Potyvirus contains more than 200 members and belongs to one of the largest plant virus
family—Potyviridae [156]. Potyviruses contain an approximately 10 kilobases positive-sense ssRNA
that is covalently linked to a viral genome-linked protein (VPg) at their 5' end via a tyrosine residue [157]
and polyadenylated at the 3'end [158–160]. The RNA has a single open reading frame that is translated
into a large polyprotein. The potyviral polyprotein is proteolytically processed into mature proteins by
dedicated virus-encoded proteases [161]. It has been suggested that VPg may serve as an analogue of
the m7G cap of the mRNAs, and plays a role in mRNA translation because of its interactions with the
cap-binding eIF4E (eIFiso4E) and eIF4F (eIFiso4F) proteins [162,163]. Studies also support a biological
role for the VPg linked to the viral RNA in virions. VPg is necessary for the infectivity of the virus [164],
cell-to-cell movement [165–170], and has been linked to a variety of other viral necessities.
Interactions between PAP and VPg were studied over a range of different temperatures using direct
fluorescence titrations. These interactions were recognized as competitive [107], because VPg competed
with the TEV RNA for PAP binding. Thermodynamics of the PAP-VPg binding were identified as
enthalpically driven and entropically favorable [107], and exhibited similarities to those of eIFiso4E- and
eIFiso4F-VPg binding [163]. Nearly one-third contribution from the TΔS van’t Hoff component to the
overall energy suggests that these interactions are driven by structural changes in both proteins, in a way
where hydrophobic residues become less solvent exposed. In addition, PAP showed greater affinity for
the viral peptide, as compared to m7GTP-cap analogue [121] and eIFiso4F [163]. Greater affinity of PAP
for VPg than that for the cap structure would produce an advantage for the cell if VPg were to localize
PAP to viral RNA for depurination. Beguilingly, VPg inhibited PAP activity by decreasing the mounts
of purines released from various RNAs [107], suggesting that it may participate in viral strategy to
overcome one of the potential host cell defense mechanisms. This is further supported Baldwin et al. [121],
and conforms to the accepted function of PAP as a RIP. Although there are suggested similarities in the
thermodynamics of PAP-VPg interactions with the eIF binding, different equilibrium dissociation
constant values point toward the differences in the active sites of PAP and the cap-binding sites of the
initiation factors.
4. Conclusions
Exploitation of RIPs as potential targets in bioterrorism, and their usage as possible antiviral and
anti-cancer agents deserve further attention. Cytotoxicity of RIPs and their effects on biological systems
present the investigators with novel ideas in exploration of new pathways for the inhibition of RIP
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activity, as well as modulation of the current inhibitors to perfect their action. These inhibitors may even
assist in controlling non-specific cytotoxicity of RIP-immunoconjugates, and serve as antidotes against
their toxicity. Recently, there has been an interest in structure-based drug design that uses the knowledge
of protein structure and its ligand interactions to identify potent enzyme inhibitors. The X-ray crystal
structures of ricin, PAP and other RIPs have been solved, and the presence of various substrate analogs
interacting with RTA side chain amino acids has been mapped out [28,30,171], identifying pivotal
residues for catalysis [172]. Kurinov et al., have reported crystal structures of PAP co-crystallized with
adenyl-guanosine (ApG) and adenyl-cytosine-cytosine (ApCpC), and showed evidence for a broad
spectrum N-glycosidase activity of PAP toward adenine-containing single stranded RNA [34]. The
inhibitory action of VPg on RIPs has not been studied in great detail, and may present researchers with
new insights in understanding not only the inhibitory mechanism of PAP and other RIPs, but also a
deeper insight into an evolutionary adaptation of plant-virus interactions, and a new direction in
understanding how these plant-pathogen relations have shaped each other for generations. Khan et al.,
have shown that VPg may serve as a cap analog [162,163], and stimulates the in vitro translation of
uncapped IRES-containing RNA to promote viral gene translation [173]. In addition, VPg inhibits
cellular capped RNA translation in wheat germ extract by recruiting the translation initiation factors
(4E and iso4E) [173]. The central domain of potyviral VPg is involved in the interactions with the eIF [174],
and alterations within VPg structure abolish these interactions [159]. The N-terminal truncation renders
VPg unable to interact with the eIF4E and eIFiso4E [159], and the binding site on VPg for the eIFs
overlaps with that for PAP binding [107]. PAP may therefore have antiviral activity both through
ribosome inactivation and RNA depurination as well as binding to VPg and potentially sequestering it.
VPg is essential for viral replication and this may be a new role for PAP in antiviral defense. Future
investigations of the inhibitory effects of VPg on other RIP activity may provide researchers with a novel
and natural peptide inhibitors of the cytotoxic activity of RIPs. This novel peptide inhibitor may aid in
non-specific inhibition of RIP activity when used as immunoconjugates in anti-cancer of anti-viral
regiments. RIP immunotoxins constitute a new modality for the treatment of cancer, since they target
cells displaying specific surface-receptors and antigens. These chimeric proteins consisting of an
antibody linked to a toxin. The antibody confers specificity (ability to recognize and react with the target),
whereas the toxin confers cytotoxicity (ability to kill the target cell) [175,176]. Immunotoxins have been used
in both mice and humans to eliminate tumor cells, autoimmune cells, and virus-infected cells [177–179].
For instance, Uckun et al., have successfully used PAP conjugated to TP-3, an IgG2b mAb that
recognizes human and canine osteosarcomas and budding capillaries of tumors, to lower the viability of
human OHS osteosarcoma cells [180,181]. However, many obstacles arise from using RIPs as
immunotoxins. Examples include, but not limited to, tissue damage on extravasation, rapid breakdown
in vivo, unfavorable pharmacokinetics, poor biodistribution, and lack of selectivity for target
tissues [152,181,182]. Immunoconjugates encapsulated into liposomes may alleviate these problems,
and have been successfully used in the past for treatment of many types of cancers [183,184].
Immunoconjugated liposomal PAP may provide a new and promising direction in cancer therapeutics,
and alleviate the above obstacles in cancer treatments.

Toxins 2015, 7

287

Acknowledgments
We thank Jean Barone for her critical review of the manuscript.
Author Contributions
Both authors, Artem V. Domashevskiy and Dixie J. Goss, have contributed equally to this
manuscript, by analyzing and surveying of the literature and data currently available on the topic.
Artem V. Domashevskiy wrote the paper.
Conflicts of Interest
The authors declare no conflict of interest.
References
1.
2.
3.
4.
5.
6.

7.

8.
9.
10.
11.
12.
13.
14.
15.

Olsnes, S. The history of ricin, abrin and related toxins. Toxicon 2004, 44, 361–370.
Christopher, G.W.; Cieslak, T.J.; Pavlin, J.A.; Eitzen, E.M. Biological warfare. A historical
perspective. JAMA 1997, 278, 412–417.
Knight, B. Ricin—A potent homicidal poison. Br. Med. J. 1979, 1, 350–351.
Wiener, S.L. Strategies for the prevention of a successful biological warfare aerosol attack.
Mil. Med. 1996, 161, 251–256.
Lodge, J.K.; Kaniewski, W.K.; Tumer, N.E. Broad-spectrum virus resistance in transgenic plants
expressing pokeweed antiviral protein. Proc. Natl. Acad. Sci. USA 1993, 90, 7089–7093.
Jach, G.; Gornhardt, B.; Mundy, J.; Logemann, J.; Pinsdorf, E.; Leah, R.; Schell, J.; Maas, C.
Enhanced quantitative resistance against fungal disease by combinatorial expression of different
barley antifungal proteins in transgenic tobacco. Plant J. 1995, 8, 97–109.
Frankel, A.E.; FitzGerald, D.; Siegall, C.; Press, O.W. Advances in immunotoxin biology and
therapy: A summary of the fourth international symposium on immunotoxins. Cancer Res. 1996,
56, 926–932.
Kreitman, R.J. Immunotoxins in cancer therapy. Curr. Opin. Immunol. 1999, 11, 570–578.
Pastan, I.; FitzGerald, D. Recombinant toxins for cancer treatment. Science 1991, 254, 1173–1177.
Christie, A. House of lurking death. In Partners in Crime; Dodd, Mead and Company: New York,
NY, USA, 1929.
Peumans, W.J.; Hao, Q.; van Damme, E.J. Ribosome-inactivating proteins from plants: More than
RNA N-glycosidases? FASEB J. 2001, 15, 1493–1506.
Irvin, J.D. Purification and partial characterization of the antiviral protein from Phytolacca americana
which inhibits eukaryotic protein synthesis. Arch. Biochem. Biophys. 1975, 169, 522–528.
Fordham-Skelton, A.P.; Taylor, P.N.; Hartley, M.R.; Croy, R.R. Characterisation of saporin
genes: in vitro expression and ribosome inactivation. Mol. Gen. Genet. 1991, 229, 460–466.
The Arabidopsis Genome Initiative. Analysis of the genome sequence of the flowering plant
Arabidopsis thaliana. Nature 2000, 408, 796–815.
Ready, M.P.; Brown, D.T.; Robertus, J.D. Extracellular localization of pokeweed antiviral protein.
Proc. Natl. Acad. Sci. USA 1986, 83, 5053–5056.

Toxins 2015, 7

288

16. Bonness, M.S.; Ready, M.P.; Irvin, J.D.; Mabry, T.J. Pokeweed antiviral protein inactivates
pokeweed ribosomes; implications for the antiviral mechanism. Plant J. 1994, 5, 173–183.
17. Domashevskiy, A.V. Turnip Mosaic Virus Genome-Linked Protein (VPg) Inhibits Pokeweed
Antiviral Protein (PAP)-Mediated Depurination of RNA. Ph.D. Thesis, Graduate Center and
Hunter College, City University of New York, New York, NY, USA, May 2012.
18. Ehrlich, P. Experimentelle Untersuchungenüber Immunität I. Ueber Ricin. Dtsch. Med. Wochenschr.
1891, 17, 976–979. (In German)
19. Ehrlich, P. Experimentelle Untersuchungenüber Immunität I. Ueber Abrin. Dtsch. Med. Wochenschr.
1891, 17, 1218–1219. (In German)
20. Lin, J.Y.; Liu, K.; Chen, C.C.; Tung, T.C. Effect of crystalline ricin on the biosynthesis of protein,
RNA, and DNA in experimental tumor cells. Cancer Res. 1971, 31, 921–924.
21. Montanaro, L.; Sperti, S.; Stirpe, F. Inhibition by ricin of protein synthesis in vitro. Ribosomes as
the target of the toxin. Biochem. J. 1973, 136, 677–683.
22. Obrig, T.G.; Irvin, J.D.; Hardesty, B. The effect of an antiviral peptide on the ribosomal reactions
of the peptide elongation enzymes, EF-I and EF-II. Arch. Biochem. Biophys. 1973, 155, 278–289.
23. Mundy, J.; Leah, R.; Boston, R.; Endo, Y.; Stirpe, F. Genes encoding ribosome-inactivating proteins.
Plant Mol. Biol. Rep. 1994, 12, S60–S62.
24. Girbes, T.; Ferreras, J.M.; Arias, F.J.; Stirpe, F. Description, distribution, activity and phylogenetic
relationship of ribosome-inactivating proteins in plants, fungi and bacteria. Mini Rev. Med. Chem.
2004, 4, 461–476.
25. Barbieri, L.; Battelli, M.G.; Stirpe, F. Ribosome-inactivating proteins from plants.
Biochim. Biophys. Acta 1993, 1154, 237–282.
26. Husain, J.; Tickle, I.J.; Wood, S.P. Crystal structure of momordin, a type I ribosome inactivating
protein from the seeds of Momordica charantia. FEBS Lett. 1994, 342, 154–158.
27. Mlsna, D.; Monzingo, A.F.; Katzin, B.J.; Ernst, S.; Robertus, J.D. Structure of recombinant ricin
A chain at 2.3 A. Protein Sci. 1993, 2, 429–435.
28. Monzingo, A.F.; Robertus, J.D. X-ray analysis of substrate analogs in the ricin A-chain active site.
J. Mol. Biol. 1992, 227, 1136–1145.
29. Savino, C.; Federici, L.; Ippoliti, R.; Lendaro, E.; Tsernoglou, D. The crystal structure of saporin SO6
from Saponaria officinalis and its interaction with the ribosome. FEBS Lett. 2000, 470, 239–243.
30. Monzingo, A.F.; Collins, E.J.; Ernst, S.R.; Irvin, J.D.; Robertus, J.D. The 2.5 A structure of
pokeweed antiviral protein. J. Mol. Biol. 1993, 233, 705–715.
31. Zhou, K.; Fu, Z.; Chen, M.; Lin, Y.; Pan, K. Structure of trichosanthin at 1.88 A resolution.
Proteins 1994, 19, 4–13.
32. Hosur, M.V.; Nair, B.; Satyamurthy, P.; Misquith, S.; Surolia, A.; Kannan, K.K. X-ray structure
of gelonin at 1.8 A resolution. J. Mol. Biol. 1995, 250, 368–380.
33. Ferreras, J.M.; Barbieri, L.; Girbes, T.; Battelli, M.G.; Rojo, M.A.; Arias, F.J.; Rocher, M.A.;
Soriano, F.; Mendez, E.; Stirpe, F. Distribution and properties of major ribosome-inactivating
proteins (28 S rRNA N-glycosidases) of the plant Saponaria officinalis L. (Caryophyllaceae).
Biochim. Biophys. Acta. 1993, 1216, 31–42.

Toxins 2015, 7

289

34. Kurinov, I.V.; Myers, D.E.; Irvin, J.D.; Uckun, F.M. X-ray crystallographic analysis of the
structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and
ribosomal RNA substrate analogs. Protein Sci. 1999, 8, 1765–1772.
35. Olsnes, S.; Pihl, A. Isolation and properties of abrin: A toxic protein inhibiting protein synthesis.
Evidence for different biological functions of its two constituent-peptide chains. Eur. J. Biochem.
1973, 35, 179–185.
36. Olsnes, S.; Pihl, A. Chimeric toxins. Pharmacol. Ther. 1981, 15, 355–381.
37. Stirpe, F.; Gasperi-Campani, A.; Barbieri, L.; Lorenzoni, E.; Montanaro, L.; Sperti, S.; Bonetti, E.
Inhibition of protein synthesis by modeccin, the toxin of Modecca digitata. FEBS Lett. 1977, 85,
65–67.
38. Sandvig, K.; Olsnes, S.; Pihl, A. Kinetics of binding of the toxic lectins abrin and ricin to surface
receptors of human cells. J. Biol. Chem. 1976, 251, 3977–3984.
39. Olsnes, S.; Sandvig, K. How protein toxins enter and kill cells. Cancer Treat. Res. 1988, 37, 39–73.
40. Steeves, R.M.; Denton, M.E.; Barnard, F.C.; Henry, A.; Lambert, J.M. Identification of three
oligosaccharide binding sites in ricin. Biochemistry 1999, 38, 11677–11685.
41. Van Deurs, B.; Tonnessen, T.I.; Petersen, O.W.; Sandvig, K.; Olsnes, S. Routing of internalized
ricin and ricin conjugates to the Golgi complex. J. Cell Biol. 1986, 102, 37–47.
42. Beaumelle, B.; Alami, M.; Hopkins, C.R. ATP-dependent translocation of ricin across the
membrane of purified endosomes. J. Biol. Chem. 1993, 268, 23661–23669.
43. Sandvig, K.; van Deurs, B. Endocytosis and intracellular sorting of ricin and Shiga toxin.
FEBS Lett. 1994, 346, 99–102.
44. Hazes, B.; Read, R.J. Accumulating evidence suggests that several AB-toxins subvert the
endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry
1997, 36, 11051–11054.
45. Lord, J.M.; Roberts, L.M. Toxin entry: Retrograde transport through the secretory pathway.
J. Cell Biol. 1998, 140, 733–736.
46. Sandvig, K.; van Deurs, B. Endocytosis and intracellular transport of ricin: Recent discoveries.
FEBS Lett. 1999, 452, 67–70.
47. Kaloyanova, D.; Kyurkchiev, S.; Xu, J.; Abouhaidar, M.; Ivanov, I. Mouse monoclonal antibodies
against Phytolacca americana antiviral protein PAP I. Hybridoma 1999, 18, 367–370.
48. Parikh, B.A.; Baykal, U.; Di, R.; Tumer, N.E. Evidence for retro-translocation of pokeweed
antiviral protein from endoplasmic reticulum into cytosol and separation of its activity on
ribosomes from its activity on capped RNA. Biochemistry 2005, 44, 2478–2490.
49. Bass, H.W.; Webster, C.; O’Brian, G.R.; Roberts, J.K.; Boston, R.S. A maize ribosome-inactivating
protein is controlled by the transcriptional activator Opaque-2. Plant Cell 1992, 4, 225–234.
50. Chaudhry, B.; Muller-Uri, F.; Cameron-Mills, V.; Gough, S.; Simpson, D.; Skriver, K.; Mundy, J.
The barley 60 kDa jasmonate-induced protein (JIP60) is a novel ribosome-inactivating protein.
Plant J. 1994, 6, 815–824.
51. Reinbothe, S.; Reinbothe, C.; Lehmann, J.; Becker, W.; Apel, K.; Parthier, B. JIP60, a methyl
jasmonate-induced ribosome-inactivating protein involved in plant stress reactions. Proc. Natl.
Acad. Sci. USA 1994, 91, 7012–7016.

Toxins 2015, 7

290

52. Walsh, T.A.; Morgan, A.E.; Hey, T.D. Characterization and molecular cloning of a proenzyme
form of a ribosome-inactivating protein from maize. Novel mechanism of proenzyme activation
by proteolytic removal of a 2.8-kilodalton internal peptide segment. J. Biol. Chem. 1991, 266,
23422–23427.
53. Jimenez, A.; Vazquez, D. Plant and fungal protein and glycoprotein toxins inhibiting eukaryote
protein synthesis. Annu. Rev. Microbiol. 1985, 39, 649–672.
54. Stirpe, F.; Barbieri, L. Ribosome-inactivating proteins up to date. FEBS Lett. 1986, 195, 1–8.
55. Barbieri, L.; Valbonesi, P.; Bondioli, M.; Alvarez, M.L.; Dal Monte, P.; Landini, M.P.; Stirpe, F.
Adenine glycosylase activity in mammalian tissues: An equivalent of ribosome-inactivating proteins.
FEBS Lett. 2001, 505, 196–197.
56. Stirpe, F.; Barbieri, L.; Gorini, P.; Valbonesi, P.; Bolognesi, A.; Polito, L. Activities associated
with the presence of ribosome-inactivating proteins increase in senescent and stressed leaves.
FEBS Lett. 1996, 382, 309–312.
57. Girbés, T.; de Torre, C.; Iglesias, R.; Ferreras, J.M.; Mendéz, E. RIP for viruses. Nature 1996, 379,
777–778.
58. Rippmann, J.F.; Michalowski, C.B.; Nelson, D.E.; Bohnert, H.J. Induction of a ribosome-inactivating
protein upon environmental stress. Plant Mol. Biol. 1997, 35, 701–709.
59. Melton-Celsa, A.R. Shiga toxin (Stx) classification, structure, and function. Microbiol. Spectr.
2014, 9, 1–13.
60. Russo, L.M.; Melton-Celsa, A.R.; Smith, M.J.; O’Brien, A.D. Comparisons of native shiga
Toxins (Stxs) Type 1 and 2 with chimeric toxins indicate that the source of the binding subunit
dictates degree of toxicity. PLoS One 2014, 9, doi:10.1371/journal.pone.0093463.
61. Brown, J.E.; Ussery, M.A.; Leppla, S.H.; Rothman, S.W. Inhibition of protein synthesis by Shiga
toxin: Activation of the toxin and inhibition of peptide elongation. FEBS Lett. 1980, 117, 84–88.
62. Sandvig, K.; van Deurs, B. Transport of protein toxins into cells: Pathways used by ricin,
cholera toxin and Shiga toxin. FEBS Lett. 2002, 529, 49–53.
63. Bergan, J.; Dyve Lingelem, A.B.; Simm, R.; Skotland, T.; Sandvig, K. Shiga toxins. Toxicon 2012,
60, 1085–1107.
64. Lam, S.K.; Ng, T.B. First simultaneous isolation of a ribosome inactivating protein and an
antifungal protein from a mushroom (Lyophyllum shimeji) together with evidence for synergism
of their antifungal effects. Arch. Biochem. Biophys. 2001, 393, 271–280.
65. Lam, S.K.; Ng, T.B. Hypsin, a novel thermostable ribosome-inactivating protein with antifungal
and antiproliferative activities from fruiting bodies of the edible mushroom Hypsizigus marmoreus.
Biochem. Biophys. Res. Commun. 2001, 285, 1071–1075.
66. Wang, H.; Ng, T.B. Isolation and characterization of velutin, a novel low-molecular-weight
ribosome-inactivating protein from winter mushroom (Flammulina velutipes) fruiting bodies.
Life Sci. 2001, 68, 2151–2158.
67. Yao, Q.Z.; Yu, M.M.; Ooi, L.S.; Ng, T.B.; Chang, S.T.; Sun, S.S.; Ooi, V.E. Isolation and
Characterization of a Type 1 Ribosome-Inactivating Protein from Fruiting Bodies of the Edible
Mushroom (Volvariella volvacea). J. Agric. Food Chem. 1998, 46, 788–792.

Toxins 2015, 7

291

68. Liu, R.S.; Yang, J.H.; Liu, W.Y. Isolation and enzymatic characterization of lamjapin, the first
ribosome-inactivating protein from cryptogamic algal plant (Laminaria japonica A). Eur. J. Biochem.
2002, 269, 4746–4752.
69. Lin, Q.; Chen, Z.C.; Antoniw, J.F.; White, R.F. Isolation and characterization of a cDNA clone
encoding the anti-viral protein from Phytolacca americana. Plant Mol. Biol. 1991, 17, 609–614.
70. Irvin, J.D.; Uckun, F.M. Pokeweed antiviral protein: Ribosome inactivation and therapeutic
applications. Pharmacol. Ther. 1992, 55, 279–302.
71. Myers, D.E.; Irvin, J.D.; Smith, R.S.; Kuebelbeck, V.M.; Uckun, F.M. Production of a pokeweed
antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B
lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
J. Immunol. Methods 1991, 136, 221–237.
72. Poyet, J.L.; Radom, J.; Hoeveler, A. Isolation and characterization of a cDNA clone encoding the
pokeweed antiviral protein II from Phytolacca americana and its expression in E. coli. FEBS Lett.
1994, 347, 268–272.
73. Rajamohan, F.; Engstrom, C.R.; Denton, T.J.; Engen, L.A.; Kourinov, I.; Uckun, F.M. High-level
expression and purification of biologically active recombinant pokeweed antiviral protein.
Protein Expr. Purif. 1999, 16, 359–368.
74. Poyet, J.L.; Hoeveler, A. cDNA cloning and expression of pokeweed antiviral protein from seeds
in Escherichia coli and its inhibition of protein synthesis in vitro. FEBS Lett. 1997, 406, 97–100.
75. Barbieri, L.; Aron, G.M.; Irvin, J.D.; Stirpe, F. Purification and partial characterization of another
form of the antiviral protein from the seeds of Phytolacca americana L. (pokeweed). Biochem. J.
1982, 203, 55–59.
76. Honjo, E.; Dong, D.; Motoshima, H.; Watanabe, K. Genomic clones encoding two isoforms of
pokeweed antiviral protein in seeds (PAP-S1 and S2) and the N-glycosidase activities of their
recombinant proteins on ribosomes and DNA in comparison with other isoforms. J. Biochem. 2002,
131, 225–231.
77. Hartley, M.R.; Lord, J.M. Genetics of ribosome-inactivating proteins. Mini Rev. Med. Chem. 2004,
4, 487–492.
78. Battelli, M.G.; Citores, L.; Buonamici, L.; Ferreras, J.M.; de Benito, F.M.; Stirpe, F.; Girbes, T.
Toxicity and cytotoxicity of nigrin b, a two-chain ribosome-inactivating protein from
Sambucus nigra: Comparison with ricin. Arch. Toxicol. 1997, 71, 360–364.
79. Duggar, B.M.; Armstrong, J.K. The effect of treating virus of tobacco mosaic with juice of various
plants. Ann. Mol. Bot. Gard. 1925, 12, 360–364.
80. Dallal, J.A.; Irvin, J.D. Enzymatic inactivation of eukaryotic ribosomes by the pokeweed antiviral
protein. FEBS Lett. 1978, 89, 257–259.
81. Kataoka, J.; Habuka, N.; Matuta, C.; Miyano, M.; Koiwai, A. Isolation and analysis of a genomic
clone encoding a pokeweed antiviral protein. Plant Mol. Biol. 1992, 20, 879–886.
82. Chen, Z.C.; Antoniw, J.F.; Hefferon, K.L.; Ivanov, I.G.; Abouhaidar, M.G. Expression of
pokeweed (Phytolacca americana) antiviral protein cDNA in Escherichia coli and its antiviral
activity. Physiol. Mol. Plant Path. 1993, 42, 237–247.
83. Xu, J.; Meng, A.X.; Hefferon, K.L.; Ivanov, I.G.; Abouhaidar, M.G. Effect of N-terminal deletions
on the activity of pokeweed antiviral protein expressed in E. coli. Biochimie 1998, 80, 1069–1076.

Toxins 2015, 7

292

84. Ago, H.; Kataoka, J.; Tsuge, H.; Habuka, N.; Inagaki, E.; Noma, M.; Miyano, M. X-ray structure
of pokeweed antiviral protein, coded by a new gwnomic clone, at 0.23 nm resolution. A model
structure provides a suitable electrostatic field for substrate binding. Eur. J. Biochem. 1994, 225,
369–374.
85. Islam, M.R.; Kung, S.S.; Kimura, Y.; Funatsu, G. N-acetyl-D-glucosamine-asparagine structure in
ribosome-inactivating proteins from seeds of Luffa cylindrica and Phytolacca americana.
Agric. Biol. Chem. 1991, 55, 1375–1381.
86. Kurinov, I.V.; Uckun, F.M. High resolution X-ray structure of potent anti-HIV pokeweed antiviral
protein-III. Biochem. Pharmacol. 2003, 65, 1709–1717.
87. Kurinov, I.V.; Rajamohan, F.; Venkatachalam, T.K.; Uckun, F.M. X-ray crystallographic analysis
of the structural basis for the interaction of pokeweed antiviral protein with guanine residues of
ribosomal RNA. Protein Sci. 1999, 8, 2399–2405.
88. Rajamohan, F.; Venkatachalam, T.K.; Irvin, J.D.; Uckun, F.M. Pokeweed antiviral protein
isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1.
Biochem. Biophys. Res. Commun. 1999, 260, 453–458.
89. Bolognesi, A.; Barbieri, L.; Abbondanza, A.; Falasca, A.I.; Carnicelli, D.; Battelli, M.G.; Stirpe, F.
Purification and properties of new ribosome-inactivating proteins with RNA N-glycosidase activity.
Biochim. Biophys. Acta 1990, 1087, 293–302.
90. Park, S.W.; Lawrence, C.B.; Linden, J.C.; Vivanco, J.M. Isolation and characterization of a novel
ribosome-inactivating protein from root cultures of pokeweed and its mechanism of secretion
from roots. Plant Physiol. 2002, 130, 164–178.
91. Barbieri, L.; Bolognesi, A.; Cenini, P.; Falasca, A.I.; Minghetti, A.; Garofano, L.; Guicciardi, A.;
Lappi, D.; Miller, S.P.; Stirpe, F. Ribosome-inactivating proteins from plant cells in culture.
Biochem. J. 1989, 257, 801–807.
92. Sperti, S.; Montanaro, L.; Mattioli, A.; Testoni, G. Relationship between elongation factor I- and
elongation factor II- dependent guanosine triphosphatase activities of ribosomes. Inhibition of both
activities by ricin. Biochem. J. 1975, 148, 447–451.
93. Barbieri, L.; Ferreras, J.M.; Barraco, A.; Ricci, P.; Stirpe, F. Some ribosome-inactivating proteins
depurinate ribosomal RNA at multiple sites. Biochem. J. 1992, 286, 1–4.
94. Barbieri, L.; Valbonesi, P.; Bonora, E.; Gorini, P.; Bolognesi, A.; Stirpe, F. Polynucleotide:
Adenosine glycosidase activity of ribosome-inactivating proteins: Effect on DNA, RNA and poly(A).
Nucleic Acids Res. 1997, 25, 518–522.
95. Endo, Y.; Mitsui, K.; Motizuki, M.; Tsurugi, K. The mechanism of action of ricin and related toxic
lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S
ribosomal RNA caused by the toxins. J. Biol. Chem. 1987, 262, 5908–5912.
96. Gutell, R.R.; Fox, G.E. A compilation of large subunit RNA sequences presented in a
structural format. Nucleic Acids Res. 1988, 16, r175–r269.
97. Chen, X.Y.; Link, T.M.; Schramm, V.L. Ricin A-chain: kinetics, mechanism, and RNA stem-loop
inhibitors. Biochemistry 1998, 37, 11605–11613.
98. Tanaka, K.S.; Chen, X.Y.; Ichikawa, Y.; Tyler, P.C.; Furneaux, R.H.; Schramm, V.L.
Ricin A-chain inhibitors resembling the oxacarbenium ion transition state. Biochemistry 2001, 40,
6845–6851.

Toxins 2015, 7

293

99. Mansouri, S.; Nourollahzadeh, E.; Hudak, K.A. Pokeweed antiviral protein depurinates the
sarcin/ricin loop of the rRNA prior to binding of aminoacyl-tRNA to the ribosomal A-site. RNA
2006, 12, 1683–1692.
100. Hudak, K.A.; Hammell, A.B.; Yasenchak, J.; Tumer, N.E.; Dinman, J.D. A C-terminal deletion
mutant of pokeweed antiviral protein inhibits programmed+1 ribosomal frameshifting and
Ty1 retrotransposition without depurinating the sarcin/ricin loop of rRNA. Virology 2001, 279,
292–301.
101. Tumer, N.E.; Parikh, B.A.; Li, P.; Dinman, J.D. The pokeweed antiviral protein specifically inhibits
Ty1-directed +1 ribosomal frameshifting and retrotransposition in Saccharomyces cerevisiae. J. Virol.
1998, 72, 1036–1042.
102. Vater, C.A.; Bartle, L.M.; Leszyk, J.D.; Lambert, J.M.; Goldmacher, V.S. Ricin A chain can be
chemically cross-linked to the mammalian ribosomal proteins L9 and L10e. J. Biol. Chem. 1995,
270, 12933–12940.
103. Hudak, K.A.; Dinman, J.D.; Tumer, N.E. Pokeweed antiviral protein accesses ribosomes by
binding to L3. J. Biol. Chem. 1999, 274, 3859–3864.
104. Di, R.; Tumer, N.E. Expression of a truncated form of ribosomal protein L3 confers resistance to
pokeweed antiviral protein and the Fusarium mycotoxin deoxynivalenol. Mol. Plant-Microbe Interact.
2005, 18, 762–770.
105. Endo, Y.; Gluck, A.; Wool, I.G. Ribosomal RNA identity elements for ricin A-chain recognition
and catalysis. J. Mol. Biol. 1991, 221, 193–207.
106. Tan, Q.Q.; Dong, D.X.; Yin, X.W.; Sun, J.; Ren, H.J.; Li, R.X. Comparative analysis of
depurination catalyzed by ricin A-chain on synthetic 32mer and 25mer oligoribonucleotides
mimicking the sarcin/ricin domain of the rat 28S rRNA and E. coli 23S rRNA. J. Biotechnol. 2009,
139, 156–162.
107. Domashevskiy, A.V.; Miyoshi, H.; Goss, D.J. Inhibition of pokeweed antiviral protein (PAP) by
turnip mosaic virus genome-linked protein (VPg). J. Biol. Chem. 2012, 287, 29729–29738.
108. Tang, S.; Xie, L.; Hou, F.; Liu, W.Y.; Ruan, K. Non-specific deadenylation and deguanylation of
naked RNA catalyzed by ricin under acidic condition. Biochim. Biophys. Acta 2001, 1519,
192–198.
109. Zamboni, M.; Brigotti, M.; Rambelli, F.; Montanaro, L.; Sperti, S. High-pressure-liquidchromatographic and fluorimetric methods for the determination of adenine released from
ribosomes by ricin and gelonin. Biochem. J. 1989, 259, 639–643.
110. Rajamohan, F.; Kurinov, I.V.; Venkatachalam, T.K.; Uckun, F.M. Deguanylation of human
immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein.
Biochem. Biophys. Res. Commun. 1999, 263, 419–424.
111. Uckun, F.M.; Rajamohan, F.; Pendergrass, S.; Ozer, Z.; Waurzyniak, B.; Mao, C. Structure-based
design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent
anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 2003, 47, 1052–1061.
112. Chen, Z.; Antoniw, J.F.; White, R.F. A possible mechanism for the antiviral activity of pokeweed
antiviral protein. Physiol. Mol. Plant Path. 1993, 42, 249–258.
113. Ussery, M.A.; Irvin, J.D.; Hardesty, B. Inhibition of poliovirus replication by a plant antiviral peptide.
Ann. NY Acad. Sci. 1977, 284, 431–440.

Toxins 2015, 7

294

114. Aron, G.M.; Irvin, J.D. Inhibition of herpes simplex virus multiplication by the pokeweed antiviral
protein. Antimicrob. Agents Chemother. 1980, 17, 1032–1033.
115. Tomlinson, J.A.; Walker, V.M.; Flewett, T.H.; Barclay, G.R. The inhibition of infection by
cucumber mosaic virus and influenza virus by extracts from Phytolacca americana. J. Gen. Virol.
1974, 22, 225–232.
116. Picard, D.; Kao, C.C.; Hudak, K.A. Pokeweed antiviral protein inhibits brome mosaic virus
replication in plant cells. J. Biol. Chem. 2005, 280, 20069–20075.
117. Uckun, F.M.; Rustamova, L.; Vassilev, A.O.; Tibbles, H.E.; Petkevich, A.S. CNS activity of
Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus
(LCMV). BMC Infect. Dis. 2005, 5, 9.
118. Ishag, H.Z.; Li, C.; Huang, L.; Sun, M.X.; Ni, B.; Guo, C.X.; Mao, X. Inhibition of Japanese
encephalitis virus infection in vitro and in vivo by pokeweed antiviral protein. Virus Res. 2013,
171, 89–96.
119. Hudak, K.A.; Wang, P.; Tumer, N.E. A novel mechanism for inhibition of translation by pokeweed
antiviral protein: Depurination of the capped RNA template. RNA 2000, 6, 369–380.
120. Hudak, K.A.; Bauman, J.D.; Tumer, N.E. Pokeweed antiviral protein binds to the cap structure of
eukaryotic mRNA and depurinates the mRNA downstream of the cap. RNA 2002, 8, 1148–1159.
121. Baldwin, A.E.; Khan, M.A.; Tumer, N.E.; Goss, D.J.; Friedland, D.E. Characterization of
pokeweed antiviral protein binding to mRNA cap analogs: Competition with nucleotides and
enhancement by translation initiation factor iso4G. Biochim. Biophys. Acta 2009, 1789, 109–116.
122. Zoubenko, O.; Hudak, K.; Tumer, N.E. A non-toxic pokeweed antiviral protein mutant inhibits
pathogen infection via a novel salicylic acid-independent pathway. Plant Mol. Biol. 2000, 44,
219–229.
123. Vivanco, J.M.; Tumer, N.E. Translation Inhibition of Capped and Uncapped Viral RNAs Mediated
by Ribosome-Inactivating Proteins. Phytopathology 2003, 93, 588–595.
124. Wang, M.; Hudak, K.A. A novel interaction of pokeweed antiviral protein with translation
initiation factors 4G and iso4G: A potential indirect mechanism to access viral RNAs.
Nucleic Acids Res. 2006, 34, 1174–1181.
125. Allen, M.L.; Metz, A.M.; Timmer, R.T.; Rhoads, R.E.; Browning, K.S. Isolation and sequence of
the cDNAs encoding the subunits of the isozyme form of wheat protein synthesis initiation
factor 4F. J. Biol. Chem. 1992, 267, 23232–23236.
126. Browning, K.S. The plant translational apparatus. Plant Mol. Biol. 1996, 32, 107–144.
127. Cheng, S.; Domashevskiy, A.; Kobilinsky, L. The Effect of Eukaryotic Initiation Factors on the
Activity of Pokeweed Antiviral Protein; Society of Toxicology: Reston, VA, USA, 2014.
128. Gallie, D.R.; Walbot, V. RNA pseudoknot domain of tobacco mosaic virus can functionally
substitute for a poly(A) tail in plant and animal cells. Genes Dev. 1990, 4, 1149–1157.
129. Gallie, D.R.; Kobayashi, M. The role of the 3'-untranslated region of non-polyadenylated plant
viral mRNAs in regulating translational efficiency. Gene 1994, 142, 159–165.
130. Williams, S.; Domashevskiy, A.V. Pokeweed antiviral protein binds to structures present in the 3'
untranslated regions of viral mRNA. In Proceeding of Annual Biomedical Research Conference
for Minority Students, San Antonio, TX, USA, 12–15 November 2014.

Toxins 2015, 7

295

131. Domashevskiy, A.V. The 3' Untranslated Regions within Viral RNA Affects Pokeweed Antiviral
Protein Antiviral Activity; American Society of Biochemistry and Molecular Biology: Rockville,
MD, USA, 2015.
132. Sandvig, K.; van Deurs, B. Entry of ricin and Shiga toxin into cells: molecular mechanisms and
medical perspectives. EMBO J. 2000, 19, 5943–5950.
133. Van Damme, E.J.; Peumans, W.J.; Barre, A.; Rouge, P. Plant lectins: a composite of several
distinct families of structurally and evolutionary related proteins with diverse biological roles.
Crit. Rev. Plant Sci. 1998, 17, 575–692.
134. Tumer, N.E.; Hudak, K.; Di, R.; Coetzer, C.; Wang, P.; Zoubenko, O. Pokeweed antiviral protein
and its applications. Curr. Top Microbiol. Immunol. 1999, 240, 139–158.
135. Dowd, P.F.; Zuo, W.N.; Gillikin, J.W.; Johnson, E.T.; Boston, R.S. Enhanced resistance to
Helicoverpa zea in tobacco expressing an activated form of maize ribosome-inactivating protein.
J. Agric. Food Chem. 2003, 51, 3568–3574.
136. Wang, P.; Tumer, N.E. Virus resistance mediated by ribosome inactivating proteins. Adv. Virus Res.
2000, 55, 325–355.
137. Craig, H.L.; Alderks, O.H.; Corwin, A.H.; Dieke, S.H.; Karel, C.L. Preparation of toxic ricin.
U.S. Patent 3,060,165, 1962.
138. Smallshaw, J.E.; Firan, A.; Fulmer, J.R.; Ruback, S.L.; Ghetie, V.; Vitetta, E.S. A novel
recombinant vaccine which protects mice against ricin intoxication. Vaccine 2002, 20, 3422–3427.
139. Mayor, S. UK doctors warned after ricin poison found in police raid. BMJ 2003, 326, 126.
140. Texas actress who sent Obama ricin sentenced to 18 years. Available online: http://www.cnn.com/
2014/07/16/justice/texas-ricin-actress-sentenced/index.html (accessed on 27 January 2015).
141. Tourlakis, M.E.; Karran, R.A.; Desouza, L.; Siu, K.W.; Hudak, K.A. Homodimerization of
pokeweed antiviral protein as a mechanism to limit depurination of pokeweed ribosomes.
Mol. Plant Path. 2010, 11, 757–767.
142. Bolognesi, A.; Polito, L. Immunotoxins and other conjugates: Pre-clinical studies. Mini Rev.
Med. Chem. 2004, 4, 563–583.
143. Hudak, K.A.; Parikh, B.A.; Di, R.; Baricevic, M.; Santana, M.; Seskar, M.; Tumer, N.E. Generation
of pokeweed antiviral protein mutations in Saccharomyces cerevisiae: Evidence that ribosome
depurination is not sufficient for cytotoxicity. Nucleic Acids Res. 2004, 32, 4244–4256.
144. Lappi, D.A.; Wiley, R.G. Immunotoxins and neuropeptide-toxin conjugates experimental applications.
Mini Rev. Med. Chem. 2004, 4, 585–595.
145. Jansen, B.; Kersey, J.H.; Jaszcz, W.B.; Gunther, R.; Nguyen, D.P.; Chelstrom, L.M.; Tuel-Ahlgren, L.;
Uckun, F.M. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe
combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein
immunotoxin plus cyclophosphamide. Leukemia 1993, 7, 290–297.
146. Uckun, F.M.; Haissig, S.; Ledbetter, J.A.; Fidler, P.; Myers, D.E.; Kuebelbeck, V.; Weisdorf, D.;
Gajl-Peczalska, K.; Kersey, J.H.; Ramsay, N.K. Developmental hierarchy during early human
B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+
B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
Blood 1992, 79, 3369–3379.

Toxins 2015, 7

296

147. Uckun, F.M.; Chelstrom, L.M.; Finnegan, D.; Tuel-Ahlgren, L.; Manivel, C.; Irvin, J.D.;
Myers, D.E.; Gunther, R. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute
lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)
pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992, 79, 3116–3129.
148. Uckun, F.M.; Chelstrom, L.M.; Irvin, J.D.; Finnegan, D.; Gunther, R.; Young, J.; Kuebelbeck, V.;
Myers, D.E.; Houston, L.L. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein
immunotoxin against BCL-1 murine B-cell leukemia. Blood 1992, 79, 2649–2661.
149. Uckun, F.M.; Manivel, C.; Arthur, D.; Chelstrom, L.M.; Finnegan, D.; Tuel-Ahlgren, L.;
Irvin, J.D.; Myers, D.E.; Gunther, R. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral
protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe
combined immunodeficiency. Blood 1992, 79, 2201–2214.
150. Erice, A.; Balfour, H.H., Jr.; Myers, D.E.; Leske, V.L.; Sannerud, K.J.; Kuebelbeck, V.; Irvin, J.D.;
Uckun, F.M. Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate
containing pokeweed antiviral protein. Antimicrob. Agents Chemother. 1993, 37, 835–838.
151. Zarling, J.M.; Moran, P.A.; Haffar, O.; Sias, J.; Richman, D.D.; Spina, C.A.; Myers, D.E.;
Kuebelbeck, V.; Ledbetter, J.A.; Uckun, F.M. Inhibition of HIV replication by pokeweed antiviral
protein targeted to CD4+ cells by monoclonal antibodies. Nature 1990, 347, 92–95.
152. Allen, T.M.; Cullis, P.R. Drug delivery systems: Entering the mainstream. Science 2004, 303,
1818–1822.
153. Baluna, R.; Vitetta, E.S. Vascular leak syndrome: A side effect of immunotherapy.
Immunopharmacology 1997, 37, 117–132.
154. Ready, M.P.; Kim, Y.; Robertus, J.D. Site-directed mutagenesis of ricin A-chain and implications
for the mechanism of action. Proteins 1991, 10, 270–278.
155. Jasheway, K.; Pruet, J.; Anslyn, E.V.; Robertus, J.D. Structure-based design of ricin inhibitors.
Toxins 2011, 3, 1233–1248.
156. Van Regenmortel, M.H.; Fauquet, C.M.; Bishop, D.H.; Carstens, E.B.; Esters, M.K.; Lemon, S.M.;
Maniloff, J.; Mayo, M.A.; McGeoch, D.J.; Pringle, C.R.; et al. Virus Taxonomy: Seventh Report
of the Interanational Committee on Taxonomy of Viruses; Academic Press: San Diego, CA,
USA, 2000.
157. Murphy, J.F.; Rychlik, W.; Rhoads, R.E.; Hunt, A.G.; Shaw, J.G. A tyrosine residue in the small
nuclear inclusion protein of tobacco vein mottling virus links the VPg to the viral RNA. J. Virol.
1991, 65, 511–513.
158. Goodfellow, I.; Chaudhry, Y.; Gioldasi, I.; Gerondopoulos, A.; Natoni, A.; Labrie, L.;
Laliberte, J.F.; Roberts, L. Calicivirus translation initiation requires an interaction between VPg
and eIF 4 E. EMBO Rep. 2005, 6, 968–972.
159. Leonard, S.; Plante, D.; Wittmann, S.; Daigneault, N.; Fortin, M.G.; Laliberte, J.F. Complex
formation between potyvirus VPg and translation eukaryotic initiation factor 4E correlates with
virus infectivity. J. Virol. 2000, 74, 7730–7737.
160. Daughenbaugh, K.F.; Fraser, C.S.; Hershey, J.W.; Hardy, M.E. The genome-linked protein VPg
of the Norwalk virus binds eIF3, suggesting its role in translation initiation complex recruitment.
EMBO J. 2003, 22, 2852–2859.

Toxins 2015, 7

297

161. Urcuqui-Inchima, S.; Haenni, A.L.; Bernardi, F. Potyvirus proteins: A wealth of functions.
Virus Res. 2001, 74, 157–175.
162. Wittmann, S.; Chatel, H.; Fortin, M.G.; Laliberte, J.F. Interaction of the viral protein genome
linked of turnip mosaic potyvirus with the translational eukaryotic initiation factor (iso) 4E of
Arabidopsis thaliana using the yeast two-hybrid system. Virology 1997, 234, 84–92.
163. Khan, M.A.; Miyoshi, H.; Ray, S.; Natsuaki, T.; Suehiro, N.; Goss, D.J. Interaction of
genome-linked protein (VPg) of turnip mosaic virus with wheat germ translation initiation factors
eIFiso4E and eIFiso4F. J. Biol. Chem. 2006, 281, 28002–28010.
164. Murphy, J.F.; Klein, P.G.; Hunt, A.G.; Shaw, J.G. Replacement of the tyrosine residue that links a
potyviral VPg to the viral RNA is lethal. Virology 1996, 220, 535–538.
165. Dunoyer, P.; Thomas, C.; Harrison, S.; Revers, F.; Maule, A. A cysteine-rich plant protein
potentiates Potyvirus movement through an interaction with the virus genome-linked protein VPg.
J. Virol. 2004, 78, 2301–2309.
166. Nicolas, O.; Dunnington, S.W.; Gotow, L.F.; Pirone, T.P.; Hellmann, G.M. Variations in the VPg
protein allow a potyvirus to overcome va gene resistance in tobacco. Virology 1997, 237, 452–459.
167. Rajamaki, M.L.; Valkonen, J.P. The 6K2 protein and the VPg of potato virus A are determinants
of systemic infection in Nicandra physaloides. Mol. Plant-Microbe Interact. 1999, 12, 1074–1081.
168. Rajamaki, M.L.; Valkonen, J.P. Viral genome-linked protein (VPg) controls accumulation and
phloem-loading of a potyvirus in inoculated potato leaves. Mol. Plant-Microbe Interact. 2002, 15,
138–149.
169. Schaad, M.C.; Carrington, J.C. Suppression of long-distance movement of tobacco etch virus in a
nonsusceptible host. J. Virol. 1996, 70, 2556–2561.
170. Schaad, M.C.; Lellis, A.D.; Carrington, J.C. VPg of tobacco etch potyvirus is a host genotype-specific
determinant for long-distance movement. J. Virol. 1997, 71, 8624–8631.
171. Rutenber, E.; Katzin, B.J.; Ernst, S.; Collins, E.J.; Mlsna, D.; Ready, M.P.; Robertus, J.D.
Crystallographic refinement of ricin to 2.5 A. Proteins 1991, 10, 240–250.
172. Kim, Y.; Mlsna, D.; Monzingo, A.F.; Ready, M.P.; Frankel, A.; Robertus, J.D. Structure of a ricin
mutant showing rescue of activity by a noncatalytic residue. Biochemistry 1992, 31, 3294–3296.
173. Khan, M.A.; Miyoshi, H.; Gallie, D.R.; Goss, D.J. Potyvirus genome-linked protein, VPg, directly
affects wheat germ in vitro translation: Interactions with translation initiation factors eIF4F and
eIFiso4F. J. Biol. Chem. 2008, 283, 1340–1349.
174. Roudet-Tavert, G.; Michon, T.; Walter, J.; Delaunay, T.; Redondo, E.; Le Gall, O. Central domain
of a potyvirus VPg is involved in the interaction with the host translation initiation factor eIF4E
and the viral protein HcPro. J. Gen. Virol. 2007, 88, 1029–1033.
175. Ghetie, V.; Vitetta, E. Immunotoxins in the therapy of cancer: From bench to clinic.
Pharmacol. Ther. 1994, 63, 209–234.
176. Pai, L.H.; Pastan, I. Immunotoxin therapy for cancer. JAMA 1993, 269, 78–81.
177. Frankel, A.E.; Tagge, E.P.; Willingham, M.C. Clinical trials of targeted toxins. Semin. Cancer Biol.
1995, 6, 307–317.
178. Ghetie, M.A.; Vitetta, E.S. Recent developments in immunotoxin therapy. Curr. Opin. Immunol.
1994, 6, 707–714.

Toxins 2015, 7

298

179. Grossbard, M.L.; Nadler, L.M. Immunotoxin therapy of lymphoid neoplasms. Semin. Hematol.
1994, 31, 88–97.
180. Anderson, P.M.; Meyers, D.E.; Hasz, D.E.; Covalcuic, K.; Saltzman, D.; Khanna, C.; Uckun, F.M.
In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed
antiviral protein. Cancer Res. 1995, 55, 1321–1327.
181. Waurzyniak, B.; Schneider, E.A.; Tumer, N.; Yanishevski, Y.; Gunther, R.; Chelstrom, L.M.;
Wendorf, H.; Myers, D.E.; Irvin, J.D.; Messinger, Y.; et al. In vivo toxicity, pharmacokinetics, and
antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin. Cancer Res.
1997, 3, 881–890.
182. Allen, T.M.; Martin, F.J. Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol.
2004, 31, 5–15.
183. Medina, O.P.; Zhu, Y.; Kairemo, K. Targeted liposomal drug delivery in cancer. Curr. Pharm. Des.
2004, 10, 2981–2989.
184. Bose, S.; Tuunainen, I.; Parry, M.; Medina, O.P.; Mancini, G.; Kinnunen, P.K. Binding of cationic
liposomes to apoptotic cells. Anal. Biochem. 2004, 331, 385–394.
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).

